A visible assay for evaluating the inhibitory activity of drug and antibody against HBV infection. [PDF]
Yan H +8 more
europepmc +1 more source
Indeterminate Phase/Grey Zone of Chronic Hepatitis B: Clinical Features, Outcomes and Molecular Insights. [PDF]
Franzè MS +5 more
europepmc +1 more source
Machine learning prediction of functional cure to pegylated interferon-alpha therapy in two HBV populations: Advantaged populations and HBeAg-negative patients. [PDF]
Li J +9 more
europepmc +1 more source
Cortisol response to corticotropin and survival in septic shock [PDF]
Angeles Marcos +18 more
core +1 more source
Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 log<sub>10</sub> IU/mL). [PDF]
Li G, Ren R, Liu J, Li J.
europepmc +1 more source
Efficacy and safety of tenofovir amibufenamide in patients with chronic hepatitis B: a real-world clinical study. [PDF]
Fan R, Fan H, Tan L, Zhang J, Ai L.
europepmc +1 more source
Hepatitis B virus RNA and hepatitis B surface antigen kinetics predict treatment outcomes in children with chronic hepatitis B. [PDF]
Peng X +8 more
europepmc +1 more source
Long-term outcomes of baseline grey-zone patients with HBeAg-negative chronic hepatitis B virus infection. [PDF]
Papatheodoridi M +9 more
europepmc +1 more source

